Profund Advisors LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 47.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,668 shares of the biopharmaceutical company’s stock after buying an additional 42,534 shares during the quarter. Profund Advisors LLC owned about 0.12% of Catalyst Pharmaceuticals worth $1,783,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its stake in Catalyst Pharmaceuticals by 241.9% during the 2nd quarter. Barclays PLC now owns 662,685 shares of the biopharmaceutical company’s stock valued at $8,907,000 after purchasing an additional 468,846 shares during the period. Denali Advisors LLC bought a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $200,000. HRT Financial LP raised its stake in Catalyst Pharmaceuticals by 551.5% during the 1st quarter. HRT Financial LP now owns 222,178 shares of the biopharmaceutical company’s stock valued at $3,683,000 after purchasing an additional 188,073 shares during the period. LSV Asset Management grew its holdings in Catalyst Pharmaceuticals by 3.1% during the 2nd quarter. LSV Asset Management now owns 987,669 shares of the biopharmaceutical company’s stock valued at $13,274,000 after buying an additional 29,869 shares in the last quarter. Finally, Strs Ohio grew its holdings in Catalyst Pharmaceuticals by 13.2% during the 2nd quarter. Strs Ohio now owns 59,200 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 6,900 shares in the last quarter. Institutional investors own 77.27% of the company’s stock.
Catalyst Pharmaceuticals Stock Performance
Shares of Catalyst Pharmaceuticals stock opened at $13.71 on Tuesday. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 26.37 and a beta of 1.08. The stock has a 50 day moving average price of $12.67 and a 200-day moving average price of $13.10. Catalyst Pharmaceuticals, Inc. has a one year low of $11.09 and a one year high of $22.11.
Analysts Set New Price Targets
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
- Five stocks we like better than Catalyst Pharmaceuticals
- How to Invest in Artificial Intelligence
- Safeguard your portfolio with these three bargain stocks
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Membership clubs gain leverage for the consumer rebound
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.